After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into mult | ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to benefit patients after surgery and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...

Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals said on Monday it will not continue development of its experimental non-opioid painkiller as a solo ...

The outcome of the study was just one setback reported by Vertex as it updated investors on its second-quarter results, ...

Vertex Pharmaceuticals ( VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically ...